CEACAM5-directed Antibody Drug Conjugate
PF-08046050, SGN-CEACAM5C is an investigational compound. Its safety and efficacy have not been established.
Overview + Rationale
- A member of the CEACAM sub-group family of glycoproteins involved in cell adhesion.1
- Highly expressed in several tumors of epithelial origin such as CRC, PDAC, GC, and NSCLC.2
- Normally expressed during fetal development but stops before birth and is restricted in adults.1,2
- CEACAM5C is an investigational antibody-drug conjugate, comprising a monoclonal antibody directed to CEACAM5 and a novel TOP1 inhibitor linker-payload system, which enables preferential release of a potent topoisomerase 1 inhibitor within target cells.3
- CEACAM5C is under investigation in advanced solid tumors.4
Mechanism of Action
![Proposed Mechanism of Action of a CEACAM5-Directed, Next-Generation Antibody-Drug Conjugate with Novel Topoisomerase 1 Inhibitor Payload](/sites/default/files/2024-05/Ceacam%20mechanism.jpg)
Stage of Development
Advanced Solid Tumors
Phase 1 Monotherapy